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ABSTRACT
Background
AML1/RUNX1 is the most frequently mutated gene in leukaemia and is central to the normal
biology of hematopoietic stem and progenitor cells. However, the role of different AML1
isoforms within these primitive compartments is unclear. Here we investigate whether altering
relative expression of AML1 isoforms impacts the balance between cell self-renewal and
differentiation in vitro and in vivo.
Methods and Findings
The human AML1a isoform encodes a truncated molecule with DNA-binding but no
transactivation capacity. We used a retrovirus-based approach to transduce AML1a into
primitive haematopoietic cells isolated from the mouse. We observed that enforced AML1a
expression increased the competitive engraftment potential of murine long-term reconstitut-
ing stem cells with the proportion of AML1a-expressing cells increasing over time in both
primary and secondary recipients. Furthermore, AML1a expression dramatically increased
primitive and committed progenitor activity in engrafted animals as assessed by long-term
culture, cobblestone formation, and colony assays. In contrast, expression of the full-length
isoform AML1b abrogated engraftment potential. In vitro, AML1b promoted differentiation
while AML1a promoted proliferation of progenitors capable of short-term lymphomyeloid
engraftment. Consistent with these findings, the relative abundance of AML1a was highest in
the primitive stem/progenitor compartment of human cord blood, and forced expression of
AML1a in these cells enhanced maintenance of primitive potential both in vitro and in vivo.
Conclusions
These data demonstrate that the ‘‘a’’ isoform of AML1 has the capacity to potentiate stem
and progenitor cell engraftment, both of which are required for successful clinical
transplantation. This activity is consistent with its expression pattern in both normal and
leukaemic cells. Manipulating the balance of AML1 isoform expression may offer novel
therapeutic strategies, exploitable in the contexts of leukaemia and also in cord blood
transplantation in adults, in whom stem and progenitor cell numbers are often limiting.
The Editors’ Summary of this article follows the references.
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AML1 (also termed RUNX1 or CBFA2), which encodes a
transcription factor, was originally identiﬁed as a component
of the fusion gene generated as a consequence of the t(8; 21)
chromosomal translocation characteristic of a subset of acute
myelogenous leukaemia [1]. Subsequently, mutations in the
AML1 gene were shown to be associated with a number of
malignant and premalignant conditions including acute
myelogenous leukaemia , childhood acute lymphocytic
leukaemia, familial platelet disorder, and myelodysplastic
syndromes. AML1 is thus the most frequently mutated gene in
human leukaemia [2,3]. Aml1 expression marks long-term
repopulating hematopoietic stem cells (HSCs) in the midg-
estation mouse embryo [4], and gene targeting experiments
have unequivocally shown Aml1 to be essential for the
development of the hematopoietic system; Aml1-null mice
die in utero of haemorrhage and lack adult-type hematopoi-
esis because of a failure in the generation of deﬁnitive HSCs
[5,6]. In contrast, conditional gene-targeting experiments
have revealed that Aml1 is dispensable for maintenance of
adult HSCs. Aml1 deﬁciency in adult stages is accompanied by
increases in myeloid progenitors and phenotypically deﬁned
HSCs, as well as impaired development of lymphoid and
megakaryocytic cells [7–9].
While AML1 is known to regulate the expression of many
hematopoietic genes, including those encoding cytokines and
their receptors as well as other transcription factors, the full
spectrum of its target genes in different cell types in normal
hematopoiesis, or AML1-associated leukaemia, remains un-
known [10,11]. Furthermore, the manner in which AML1 is
itself regulated at the level of transcription and post-
transcriptional processing is largely not understood [12].
Addressing these issues will be essential to understanding how
AML1 plays such a crucial role in both normal and leukaemic
hematopoiesis. Potentially confounding factors in these
endeavours are the large size of the AML1 locus, the
complexity of its putative regulatory elements, and the
prevalence within the AML1 gene of extensive alternative
splicing [13–15].
Evidence is accumulating that isoforms of key hemato-
poietic transcription factors can play both distinct and key
regulatory roles in hematopoiesis. A case in point is GATA1,
which regulates the differentiation of erythroid and mega-
karyocytic cells [16]. Full-length GATA1 is composed of an
amino-terminal transactivation domain as well as two zinc
ﬁngers that mediate its binding to DNA. However, an isoform
lacking the transactivation domain is also expressed. This
short form is impaired in its ability to promote differ-
entiation and is implicated in abnormal hematopoiesis
associated with Down syndrome [17,18]. Similarly, truncated
forms of SCL/TAL1 favour erythroid lineage development,
whereas full-length forms enhance the development of the
megakaryocytic lineage [19]. An alternatively spliced isoform
of TEL/ETV6 has recently been shown to inhibit, in a
dominant-negative manner, the activity of full-length TEL
and thereby negatively regulate the TEL-mediated erythroid
differentiation of mouse erythroleukaemia cells [20]. Finally,
enforced expression of an isoform of IKAROS/IKZF (IKAROS
6), which lacks the DNA-binding domain, in human CD34
þ
cells limits B cell development [21]. IKAROS isoforms are also
implicated in the development of leukaemia [22–24].
The human AML1 gene generates three alternatively
spliced variants, AML1a, AML1b, and AML1c [25]. AML1b
and AML1c both possess the DNA-binding region (runt
domain) at the amino-terminal end as well as the carboxyl-
terminal transcriptional regulatory domains; AML1b and
AML1c are therefore considered to be broadly similar in
function. In contrast, AML1a retains the DNA-binding
domain, but lacks the transcriptional regulatory domains.
AML1a is thus considered a potential functional antagonist of
AML1b and AML1c [25]. The opposing functions of AML1a
and AML1b have been shown in myeloid-committed cell lines
with respect to their granulocyte colony-stimulating factor
(G-CSF)–induced differentiation programmes; ectopically
expressed AML1a blocks granulocytic differentiation, and
this blockade is released by enforced expression of AML1b.
Differentiation arrest in this cell-line model is accompanied
by uncompromised growth under culture conditions that
normally induce differentiation in the parental cell line [26].
AML1a transcripts have also been noted in selected leukaemia
samples, as have mutant truncated forms of the AML1
protein that structurally resemble AML1a [26–29]. However,
little is known about the potentially differential roles of
AML1 isoforms in regulating normal or leukaemic cell fates
in the stem and progenitor compartment of hematopoiesis.
To address these questions, we expressed AML1a and AML1b
in primary murine bone marrow (BM)-derived hematopoietic
stem/progenitor cells and analysed the resulting effects on
hematopoiesis both in vitro and in vivo. We then performed
similar experiments in the corresponding human compart-
ments. Such studies may lead to new strategies for the
manipulation of haematopoietic progenitors and inform
future treatments for haematological malignancies
Methods
Generation of Retroviruses
cDNAs for AML1a and AML1b [25] (generous gifts of Misao
Ohki, National Cancer Center, http://www.ncc.go.jp) tagged
with the FLAG-epitope at the amino terminal were cloned
upstream of the internal ribosome entry site (IRES) element
into the EcoRI/XhoI restriction site of the murine stem cell
virus–internal ribosome entry site–green ﬂuorescent protein
(GFP) vector (MSCV-IRES-GFP) [30]. The MSCV-IRES-human
CD4 vector that expresses an extracellular portion of the
human CD4 molecule was generously provided by Jason G.
Cyster (University of California San Francisco, http://www.
ucsf.edu) [31]. Retrovirus vector plasmids were transiently
transfected into Phoenix-Eco packaging cells (obtained from
American Type Culture Collection, http://www.atcc.org) by a
standard calcium phosphate precipitation method. Virus
supernatants were then concentrated by centrifugation
before use in infecting cells [32].
Retroviral Infection of Mouse BM Cells and
Transplantation
BM cells were harvested from tibiae and femora of BALB/c
mice 4 d after intravenous administration of 5-ﬂuorouracil
(5-FU) (150 mg/kg) and treated with ACK (0.15 M NH4Cl, 1.0
mM KHCO3, 0.1 mM EDTA) to lyse red blood cells. BM cells
were then prestimulated with stem cell factor (SCF) (100 ng/
ml) þ interleukin (IL) 3 (IL3) (10 ng/ml) þ IL6 (6 ng/ml)
(Peprotech, http://www.peprotech.com) for 24 h and spin-
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and polybrene (4 lg/ml) (Sigma, http://www.sigmaaldrich.com)
[32]. Cells (1 3 10
6) were transplanted intravenously into
lethally irradiated (7.5 Gy) recipient mice, which were
maintained on acidiﬁed water throughout the experimental
period [32]. In some experiments, lin
 c-kit
þ hematopoietic
progenitor cells sorted from C57BL6 mice were used, in place
of 5-FU-treated BM cells. Results obtained using the two
different sources of cells were essentially identical. For
competitive repopulation, BM cells from the 5-FU-treated
mice were infected with retroviruses for either GFP only,
AML1a, or human CD4. Cells were then admixed to obtain
mixtures of GFP-transduced and CD4-transduced cells, or
AML1a-transduced and CD4-transduced cells for transplan-
tation.
Flow Cytometry of Mouse Cells
After red blood cell lysis, cells were incubated with the
indicated antibodies, conjugated with either one of phycoer-
ythrin, biotin, or allophyocyanin (APC); biotinylated anti-
bodies were then stained with streptavidin-APC or
streptavidin-peridinin-chlorophyll-protein Cy5.5. Nonspe-
ciﬁc binding was blocked by preincubation with an anti-Fc
receptor antibody (2.4G2). Antibodies used were as follows:
anti-CD3 (145–2C11), anti-CD4 (RM4–5), anti-CD8 (53–6.7),
anti-B220 (RA3-6B2), anti-CD19 (1D3 and MB19–1), anti-
TER-119 (TER-119), anti-Gr-1 (RB6-8C5), anti-Mac-1 (M1/70),
anti-c-kit (2B8), anti-CD34 (RAM34), anti-Sca-1 (D7), and
anti-human CD4 (RPA-4). Isotype-matched Ig was used as a
control. Antibodies were obtained from BD Biosciences
(http://www.bdbiosciences.com) and eBioscience (http://www.
ebioscience.com). Cells were washed with PBS containing 1%
fetal calf serum and analysed on a FACSCalibur (BD
Biosciences) with CELLQUEST software. Cell sorting was
conducted with a FACSVantage (BD Biosciences).
Western Blot Analysis
Total cell lysates were fractionated by SDS-PAGE and
blotted onto a nylon membrane. AML1a and AML1b were
detected with an anti-AML1 antibody (Ab-2, Oncogene
Research Products, http://www.merckbiosciences.co.uk) or an
anti-FLAG antibody (M2, Sigma). Anti-tubulin antibody
(Sigma) was used to allow comparison of loaded protein
amounts. Primary staining was visualized with a goat anti-
rabbit Ig- horseradish peroxidase (HRP) conjugate, a goat
anti-mouse Ig–HRP conjugate, or a secondary antibody by
using enhanced chemiluminescence (Amersham Bioscience,
http://www.amersham.com). Western blot analysis of primary
human cord blood was conducted using a 12% acrylamide
gel, and the AML1 proteins were detected using an anti-
AML1 antibody (Ab-2) in combination with the highly
sensitive West Femt reagent (Pierce, http://www.piercenet.
com).
In Vitro Colony-Forming Assays of Mouse Cells
Cells were plated in triplicate in methylcellulose under
multimyeloid differentiation conditions (SCF [50 ng/ml], IL3
[10 ng/ml], IL6 [10 ng/ml], and erythropoietin [Epo, 3 units/
ml]) (Methocult M33342, Stem Cell Technology, http://
www.stemcell.com), or myelomonocytic differentiating con-
ditions (SCF [50 ng/ml], IL3 [10 ng/ml], IL6 [10 ng/ml], and
granulocyte/macrophage-CSF [GM-CSF; 10 ng/ml]). Colonies
were typed and counted at day 7. For colony-forming unit
(CFU) megakaryocyte (meg) (CFU-meg), a-MEM supple-
mented with 0.8% methylcellulose, 1% BSA, 30% FBS, 0.1
mM 2-mercaptoethanol, and 10 units of mouse thrombo-
poietin (Peprotech) was used [7].
In Vitro Culture of Mouse Cells
Transduced cells were maintained in Iscove’s modiﬁed
Dulbecco’s medium (Gibco, http://www.invitrogen.com) sup-
plemented with 10% fetal calf serum in the presence of SCF
(50 ng/ml) and IL3 (10 ng/ml). Cytokines were purchased from
Peprotech.
Cell-Cycle Analysis
Cells in culture were incubated with 10 lM of 5-bromo-29-
deoxyuridine (BrdU) (WAKO, http://www.wako-chem.co.jp/
english) for 30 min and then ﬁxed in 70% cold ethanol and
treated with 4 N HCl. Incorporated BrdU was visualized by
anti-BrdU antibody conjugated to ﬂuorescein (BU.1, Chem-
icon International, http://www.chemicon.com) and analysed
on a FACSCalibur along with DNA content as stained by
propidium iodide.
Long-Term Culture–Initiating Cell and Cobblestone Area-
Forming Cells Assays for Mouse Cells
For long-term culture-initiating cell (LTC-IC) assays, GFP
þ
and GFP
  cells from the lin
  compartment were sorted from
mouse BM by ﬂow cytometry and inoculated onto pre-
established irradiated stromal cells by limiting dilution in
Myelocult medium (Stem Cell Technology). Cells were
cultured for 4 wk and then subjected to colony formation
assay in Methocult M33342, following the manufacturer’s
instructions. For cobblestone area-forming cell (CAFC)
assays, the stromal cell line FBMD-1 (a kind gift from Dr.
Gary Van Zant, University of Kentucky, ttp://www.uky.edu)
was used. Total BM cells sorted on the basis of GFP
expression were inoculated onto the pre-established stromal
cell layer by limiting dilution and cultured for 5 wk.
Cord Blood
Cord blood cells were collected, with written informed
consent, for use in research. Total CD34
þ cells and total
CD15
þ cells were puriﬁed using MACS magnetic beads
(Miltenyi Biotec, http://www.miltenyibiotec.com) according
to the manufacturer’s instructions. CD34
þ subsets were
isolated by cell sorting using antibodies against human
CD14, CD19, CD33, and CD133. For the isolation of CD36
þ
cells, puriﬁed CD34
þ cells were cultivated in vitro with SCF
(50 ng/ml), IL3 (20 ng/ml), and IL6 (20 ng/ml) for 7 d and
isolated using a CD36-PE antibody in combination with anti-
PE magnetic beads [33]. The resulting cells gave 98%
erythroid output when plated in methylcellulose containing
SCF, IL3, IL6, GM-CSF, G-CSF, and Epo.
Quantification of AML1 Isoforms in Human Cord Blood by
Reverse Transcription-PCR
Primers 59-GAGGGAAAAGCTTCACTCTGA-39 (primer C),
GTGTACCGGGATCCATGCTA-39 (primer 3A), and 59-
GTTGAGAGTCGACTGGAAAG-39 (primer 2B) were used to
detect AML1a (primers C and 3A) and AML1b/AML1c (primers
C and 2B) as described [25]. PCR products thus obtained were
then used as templates for additional PCR with the following
primer sets to generate competitor DNAs: 59-TTTGAATTC-
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CATCGGCA-39 (primer C9), 59-TTTGAATTCGTGTACCGG-
GATCCATGCTA-39 (primer 3A9), and 59-
TTTGAATTCGTTGAGAGTCGACTGGAAAG-39 (primer
2B9). These primer sets were designed to generate products
157 bp shorter than the authentic PCR products and to
facilitate subcloning. PCR products with primers C9 and 3A9,
or with primers C9 and 2B9, were digested with EcoRI, and
inserted into the EcoRI site of the pBluescript vector
(Stratagene, http://www.stratagene.com) to obtain pBS/com-
petitor A and pBS/competitor B. NotI/XhoI fragment of pBS
competitor A was then inserted into NotI/XhoI site of the
pMXs vector, then the EcoRV/XhoI fragment was inserted
into the EcoRV/XhoI site of the pBS/competitor B. The
plasmid thus obtained (pBS/competitor A þ B) contained
competitors for AML1a and AML1b in back-to-back orienta-
tion, with 1,250 bp of intervening spacer. This pBS/
competitor A þ B was used for the competitive PCR for both
AML1a and AML1b/AML1c to quantitate AML1 isoforms in a
given cell population [34]. Total RNA was isolated from the
fractionated cord blood cells using Trizol reagent (Invitrogen,
http://www.invitrogen.com) and then reverse-transcribed
using random primers and Superscript II enzyme according
to the manufacturers’ instructions. cDNA thus obtained was
then mixed with known amounts of the competitor plasmid
and PCR was conducted either with primer sets C and 3A, or
with primer sets C and 2B. PCR products were then
fractionated on a 2.5% agarose gel electrophoresis, and the
PCR products from endogenous AML1 and from the
competitor plasmid were quantitated densitometrically. The
amounts of the endogenous AML1 isoforms were then
estimated as described [34] and normalized on the basis of
G6PD expression estimated by a quantitative real-time PCR
[35].
Preparation of Lentivirus and Cord Blood Cell
Transduction
An AML1a cDNA was cloned into the pHR-SINCSGW
lentivirus [36], which carries an emerald-GFP reporter.
Lentiviruses were pseudotyped with the vesicular stomatitis
virus G (VSVG) protein by transient transfection of 293T
cells. High-titre viral stocks were prepared by ultracentrifu-
gation [37]. CD34-enriched cord blood cells were infected for
24 h by lentivirus (either AML1a or control virus) with MOI of
100 in serum free medium Stem/Span (Stem Cell Technolo-
gies) supplemented with SCF (100 ng/ml), FLT-3 ligand (100
ng/ml), thrombopoietin (20 ng/ml), and IL6 (20 ng/ml) (all
growth factors were from Peprotech) [38,39].
In Vitro Analysis of Human Cells
Colony-forming cell (CFC) assays with human cells were
under serum-free conditions with recombinant human SCF,
G M - C S F ,I L 3 ,I L 6 ,G - C S F ,a n dE p o( M e t h o C u l tH 4 5 3 6 ,
StemCell Technologies). LTC-IC assays with human cells
were performed in 96-well format in Myelocult H5100
medium (StemCell Technologies) on a feeder layer compris-
ing a 1:1 mixture of irradiated M210B4 and S1/S1 mouse
ﬁbroblasts [40]. For limiting dilution CAFC assays MS-5
stroma cells [41] were maintained in a-MEM medium
complemented with 2 mM L-glutamine, 2 mM sodium
pyruvate, 10% FBS (Stem Cell Technologies). After the cells
were inoculated, weekly half medium changes were per-
formed for the duration of the culture. CFAC were scored at
6 wk [42,43].
Nonobese Diabetic–Severe Combined Immunodeficient
Mice and Transplantations
Nonobese diabetic–severe combined immunodeﬁcient
(NOD-SCID) mice were bred and maintained at the Weath-
erall Institute of Molecular Medicine (WIMM) animal facility
in accordance with Home Ofﬁce regulations (United King-
dom). Animals were handled under sterile conditions. Trans-
plantations were performed by tail-vein or intrafemoral
injection into 6- to 10-wk-old mice. Recipients received 350
cGy of total body irradiation, and BM engraftment was
assessed at 8 wk post-transplantation. Human cell engraft-
ment was assessed by staining of BM cells with anti-CD19-
APC (DAKO), anti-CD34-PE (BD Biosciences Pharmingen),
anti-CD45-APC (DAKO, http://www.dako.com), and CD38-
FITC (DAKO).
Results
Effects of AML1a and AML1b on Long-Term Engrafting
Cells and Hematopoiesis In Vivo
BM cells were isolated from 5-FU-treated mice and
transduced with murine stem cell virus -based retroviruses
containing amino-terminal FLAG-tagged AML1a or AML1b
inserted upstream of an IRES-GFP cassette (Figure 1A). GFP
þ
and GFP
  cells (Figure 1B) were separated by ﬂow cytometry,
and expression of AML1a and AML1b were conﬁrmed by
Western blotting using an antibody directed against a peptide
within the AML1 runt domain (Figure 1C), which also detects
endogenous murine Aml1; the identity of the AML1a and
AML1b were additionally conﬁrmed by Western blotting with
an antibody directed against the FLAG tag (Figure 1C). These
results also showed that the expression level of exogenous
AML1a and AML1b was less than 2-fold that of endogenous
Aml1 in the cells used subsequently for transplantation.
Animals were transplanted in cohorts to facilitate kinetic
studies of engraftment (Table 1). The contribution of control
vector-transduced cells was relatively stable over time in all
cohorts followed. AML1b-transduced cells, in contrast, never
contributed to BM at 1 mo or thereafter. Strikingly, the
contribution of AML1a-transduced cells increased with time;
in a typical case (cohort 4), percentage GFP was 10.5% at 3.5
mo, 11.4% at 4 mo, 42.2% at 11.5 mo, and 53.4% at 12 mo.
Western blotting showed that exogenous AML1a expression
was 2- to 3-fold higher than endogenous Aml1 and conﬁned
exclusively to GFP
þ cells within the graft (Figure 1D). These
results suggest that while AML1b expression abrogates
engraftment potential, AML1a expression confers a growth
advantage on BM cells in vivo.
We therefore examined this growth advantage using
competitive repopulation assays. Competitor cells marked
by expression of the extracellular domain of a human CD4
were mixed with either AML1a- or control vector-transduced
cells just prior to transplantation into cohorts of lethally
irradiated mice. In one cohort, a mixture of 6.2% of GFP
þ
control vector-transduced cells and 4.0% of human CD4
þ-
transduced competitor cells were used for the transplanta-
tion. In the second cohort, a mixture of 4.5% GFP
þ AML1a-
transduced cells and 5.7% of human CD4
þ-transduced
competitor cells were used. Subsequent analysis of engrafted
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engraftment potential of AML1a-expressing cells to be
substantially higher than their control-vector transduced
counterparts. Kinetic studies conducted over a 9-mo period
(Table 2) showed the ratio of GFP and CD4 to be relatively
stable in the control-vector/CD4 cohort. In contrast, the GFP/
CD4 ratio increased with time in the AML1a/CD4 mice cohort
(Table 2). This property was also evident in the secondary
transplantation experiments: when BM cells from a primary
recipient exhibiting GFP/CD4 ratio ¼ 1.6 at 3 mo post-
transplant were secondarily transplanted, the secondary
recipients displayed ratios of 3.0 6 1.41 (mean 6 standard
deviation) at 3 mo and 9.0 6 3.29 at 8 mo post-transplant.
This increase in the GFP/CD4 ratio was not seen in mice
secondarily transplanted with BM cells taken from control
(control-vector/CD4) cohorts. Collectively, these results sug-
gest that expression of AML1a confers a high level of
competitive engraftment potential.
We explored this competitive potential further by examin-
ing the status of the primitive progenitor compartment in
primary AML1a recipients. We determined the number of c-
Kit
þSca-1
þLin
  (KSL) cells within GFP
þ and GFP
  fractions of
BM in each of six AML1a and six control animals 6 mo post-
transplantation, and the results are shown pairwise for
individual mice in Figure 2A. No difference in KSL frequency
was observed between GFP
þ and GFP
  fractions from control
animals. In contrast, the GFP
þ fractions of AML1a mice
contained signiﬁcantly more KSL than the corresponding
GFP
  fractions of the same animals. Interestingly, however,
percentage KSL was not signiﬁcantly different between the
GFP
þ fractions of AML1a and control animals. This result
may reﬂect the relative competitiveness of GFP
þ and GFP
 
cells within the BM of a single animal, or alternatively
percentage KSL may not entirely reﬂect the frequency of
functional stem and multipotent progenitors. We therefore
quantitated the number of functional primitive hemato-
Figure 1. Transduction of Mouse HSCs with AML1 Isoform-Containing Retroviruses
(A) Recombinant viruses.
(B) FACS analysis of GFP expression in infected hematopoietic cells immediately after infection with control, AML1a-containing, or AML1b-containing
viruses.
(C) Western blot analysis of lysates from cells sorted immediately after infection by using anti-AML1, anti-Flag, and anti-tubulin antibodies. The anti-
AMLl antibody was raised against the Runt domain and therefore detected both human and endogenous mouse AML proteins.
(D) Western blot analysis of GFP
þ and GFP
  BM cells from animals 4 mo after the transplantation (antibodies as in [C]).
(E) Typical FACS analyses of BM cells from competitive repopulation assays of AML1a-transduced cells. BM cells of mice transplanted with mixtures of
human CD4
 and GFP-only-control-transduced cells (a) or human CD4
 and AML1a-transduced cells (b) were analysed for expression of human CD4 and
GFP.
doi:10.1371/journal.pmed.0040172.g001
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from one such experiment are shown in Figure 2B and 2C. In
the case of LTC-IC assays, GFP
þlin
  and GFP
 lin
  cells were
isolated from transplanted animals by ﬂow cytometry and
cocultured using the limiting dilution method on pre-
established BALB/c mouse BM stromal layers. After 4 wk of
culture, the cells were harvested and assayed for CFC activity
to enumerate the frequency of primitive hematopoietic cells.
In the case of CAFC assays, total GFP
þ or GFP
  cells were
puriﬁed from transplanted mice and cultured using the
limiting dilution method on FBMD-1 cell line stromal layers;
cobblestone areas, comprising six or more cells, were
enumerated 5 wk later. These in vitro assays revealed a
signiﬁcant increase in the frequency of primitive hemato-
poietic cells in AML1a-positive BM-fraction; comparison of
the GFP
þ versus GFP
  fractions showed a 4-fold increase (1/
388.1 versus 1/1,666.2) in LTC-IC (Figure 2B) within lin
  cells
and a 14-fold increase (1/7,808.2 versus 1/10,9187.2) in CAFC
(Figure 2C) within unfractionated cells. These increases were
not seen in the corresponding fractions of cells from control
animals (Figure 2B and 2C).
We next examined the committed progenitor compart-
ment using CFC assays. GFP
þ cells from AML1a mice
displayed increased total CFC activity (Figure 2D) primarily
in granulocyte- and/or macrophage-restricted (CFU-GM) and
primitive mixed lineage (CFU-mix) progenitors. Further-
more, AML1a-expressing colonies (GFP
þ) were larger than
those produced from control cells (GFP
 ) from the same
animals (Figure 2E). AML1a expression did not alter the
frequency of erythroid colonies (erythropoietic burst for-
mation) generated but was associated with an increase in
CFU-meg formation (Figure 2D), but cells in these CFU-meg
colonies were smaller than controls, displaying hypolobulated
nuclei indicative of impaired differentiation (unpublished
data). Consistent with these CFC data, the lin
 c-kit
þ progen-
itor compartment was increased 4.0-fold in the GFP
þ versus
GFP
  fraction in animals transplanted with AML1a-trans-
duced BM, and these animals also displayed increases in
immature blast-like cells (Figure S1). Morphological exami-
Table 1. Kinetic Analysis of Engraftment of AML1a-, AML1b-, and Control Vector-Transduced BM Cells
Category Cohort Percentage GFP
in Transplanted Cells
Percent GFP in BM Cells after Transplantation
Control 1 (n ¼ 3) 16.2% 18.1% (2.5 mo), 22.4% (7 mo), 27.4% (12 mo)
2( n ¼ 4) 12.1% 27.4% (2.5 mo), 23.6% (3 mo), 32.4% (12 mo), 33.4% (12 mo)
3( n ¼ 3) 5.7% 5.4% (3 mo), 4.8% (3 mo), 7.2% (12 mo)
Aml1a 1( n ¼ 3) 10.5% 51.4% (3 mo), 67.2% (12 mo), 62.1% (12 mo)
2( n ¼ 4) 7.6% 21.4% (5.5 mo), 26.7% (5.5 mo), 47.6% (11.5 mo), 44.3% (11.5 mo)
3( n ¼ 4) 9.6% 11.4% (1 mo), 12.1% (1 mo), 20.6% (3 mo), 22.4% (3 mo)
4( n ¼ 4) 5.4% 10.5% (3.5 mo), 11.4% (4 mo), 42.2% (11.5 mo), 53.4% (12 mo)
Aml1b 1( n ¼ 3) 22.4% ,1% (1 mo), ,1% (1 mo), ,1% (1 mo)
2( n ¼ 3) 20.5% ,1% (1 mo), ,1% (1 mo), ,1% (1 mo)
3( n ¼ 3) 14.3% ,1% (1 mo), ,1% (1 mo), ,1% (1 mo)
BM cells from 5-FU-treated mice were transduced with the AML1a-o rAML1b-containing and GFP-only control retrovirus and transplanted into cohorts of lethally irradiated syngeneic
hosts to allow analysis of engraftment over time. The table shows the percentage of GFP
þ cells in the starting transplant material as well as the level of GFP positivity observed in the
marrow of each animal analysed at the various post-transplantation time points indicated in a given cohort.
doi:10.1371/journal.pmed.0040172.t001
Table 2. Competitive Repopulation Assays of AML1a-Transduced Cells in First and Second Transplantations
BM
Transplantation
Months GFP/CD4 Ratio Nonparametric
Trend Test
Aml1a/CD4 Ratio Nonparametric
Trend Test Transplanted Observed
Median (Range)
Transplanted Observed
Median (Range)
First 3 1.6 1.69 (1.63–2.04) N.S. 0.79 1.55 (1.41–1.68) p , 0.01
6 (6.2%:4.0%) 1.48 (1.19–1.77) (4.5%:5.7%) 3.88 (3.12–6.05)
9 2.18 (1.68–2.32) 17.7 (9.38–18.2)
Second 3 1.6 1.14 (0.83–2.29) N.S. 1.6 2.37 (1.95–4.57) p , 0.05
8 (7.8%:4.8%) 2.45 (2.17–4.88) (6.2%:4.0%) 7.26 (6.88–12.8)
3 1.7 1.48 (1.43–2.21) N.S. 1.4 (7.2%:5.1%) 2.96(2.01–3.60) p , 0.05
8 (6.1%:3.6%) 1.48 (1.29–2.02) 6.40 (5.22–8.23)
Ratios of cells expressing human CD4 and GFP just before transplantation were 1.6 for a mixture of GFP-only control and human CD4-transduced cells and 0.79 for a mixture of AMLa- and
human CD4-transduced cells. Cells were transplanted into nine mice each, and then three mice each were sacrificed 3, 6, and 9 mo after transplantation. Ratios of GFP/hCD4 were analysed
by flow cytometry as shown in Figure 2, and the median and range in each of the three mice are presented. The GFP/CD4 ratios were not statistically different at any time of analysis for
GFP-only control, but AML1a/CD4 ratios increased with time (p , 0.01; nonparametric trend test). BM cells taken from mice 3 mo after primary transplantation (above) were then used for
secondary transplantation. BM cells from mice showing GFP-only control/hCD4 ratios 1.6 and 1.7 were transplanted into six mice each. Mice were then sacrificed 3 and 8 mo after the
secondary transplantation and analysed for GFP/hCD4 ratios. The ratios were not different between 3 and 8 mo. Similarly, BM cells from mice showing AML1a/hCD4 ratios 1.6 and 1.4 were
transplanted into six mice each, and expressions of GFP and hCD4 were analysed 3 and 8 mo later. In this case again, the AML1a/hCD4 ratios increased over time (p , 0.05; nonparametric
trend test). N.S., not significant.
doi:10.1371/journal.pmed.0040172.t002
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Isoform-Specific Effects of AML1Figure 2. Analysis of BM Compartments in Engrafted Animals
Results from GFP
þ and GFP
  cells are shown in solid and open symbols, respectively.
(A) Percentages of KSL cells in GFP
þ and GFP
  fraction of individual animals are presented pairwise. All animals were analysed 4 mo after
transplantation. Statistical significance was evaluated using Wilcoxon and Mann-Whitney tests.
(B) LTC-IC analysis of GFP
þ and GFP
  cells from the lin
  BM compartment of AML1a and control animals. LTC-IC frequency within the lin
  compartment
and its 95% confidence interval (in parenthesis) are presented. Two independent experiments gave a similar result.
(C) CAFC analysis of GFP
þand GFP
 cells from total BM of AML1a and control animals. Wells containing clusters of six or more cobblestone cells after 35
d of culture were scored as positive, and the frequency of CAFC calculated by Poisson statistics; CAFC frequency and its 95% confidence interval (in
parenthesis) are presented. Two independent experiments gave a similar result.
(D) Colony-forming activity BM cells sorted from an AML1a animal and cultured under multimyeloid (CFU-GM, erythropoietic burst formation [BFU-E],
and CFU-mix) and megakaryocytic (CFU-meg) conditions are shown. Representative data from three independent experiments conducted in triplicate
are presented. Asterisks indicate statistical significance of the difference estimated by Mann-Whitney test.
(E) Photomicrographs show relative sizes of colonies generated in multimyeloid condition.
doi:10.1371/journal.pmed.0040172.g002
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Isoform-Specific Effects of AML1nation of sorted BM cells from AML1a and control mice also
revealed an over-representation of myeloid versus lymphoid
cells in the GFP
þ fraction of AML1a-mice (Figure S1A), which
was conﬁrmed by immunophenotyping (unpublished data).
There were no morphological or immunophenotypic indica-
tions of arrested differentiation in the AML1a-expressing
myeloid compartment (Figure S1B and S1C).
AML1a and AML1b Display Opposing Effects on Myeloid
Differentiation In Vitro
The abrogation of engraftment by AMLb precluded further
analysis of its effects on haematopoietic cells in vivo. We
therefore compared effects of AMLb and AML1a on the
clonogenic activity of appropriately transduced 5-FU cells
(see Figure 1A and 1B) in vitro using CFU in culture assays.
The total number of colonies was similar in AML1a- and
control vector-transduced cells, but signiﬁcantly reduced in
AML1b-expressing cells (Figure 3A). Upon serial replating—
an assay of self-renewal—AML1b-expressing cells gave rise to
signiﬁcantly fewer colonies than control vector-transduced
cells at all passages examined, whereas expression of AML1a
produced more colonies. Furthermore, compared with
colonies produced by control vector-transduced cells, colo-
nies from AML1a-expressing cells were larger, whereas
colonies from AML1b-expressing cells were smaller (Figure
S2A). Analysis of cell-cycle status, as assessed by using BrdU
incorporation and DNA content, revealed that AML1a-
expressing cells were more proliferative than controls or
AML1b-expressing cells (Figure 3B and 3C). Results of colony
typing and morphological assessment of cells within primary
colonies are shown in Figure 3D. AML1b-expressing cells
produced no erythroid output and gave rise to signiﬁcantly
more granulocyte-restricted CFU (CFU-G) than control cells.
The overall distribution of colony type produced by AML1a-
expressing cells was similar to that seen in controls, but the
granulocytic component within CFU-GM colonies was mark-
edly decreased (unpublished data). AML1b-expressing cells
did not produce CFU-meg colonies (Figure 3E). In contrast,
AML1a cells produced more CFU-meg than controls (Figure
3E). When compared with vector-transduced control cells, the
Gr-1-high mature granulocytic fraction was increased by
AML1b expression and decreased by AML1a expression in
both multimyeloid and myelomonocytic conditions. How-
ever, upon replating, AML1a-expressing cells started to
express high levels of Gr-1 (Figure 3F), which was accom-
panied by the appearance of morphologically mature
granulocytes (Figure 3G). Similar results were obtained when
cells were plated under myelomonocytic- (SCF þ IL3 þ IL6 þ
GM-CSF) promoting culture conditions (unpublished data).
Collectively, these ﬁndings suggest that AML1b expression
promotes granulocytic differentiation at the expense of
alternative lineages, and AML1a expression retards but does
not block granulocytic maturation of BM cells under the
conditions used while promoting self-renewal and prolifer-
ation of progenitor cells. Furthermore, AML1a-transduced
cells recovered from the third round of replating propagated
in suspension culture, displaying a cumulative cell expansion
of about 10
14-fold in 9 wk (Figure 4A). The cultures
comprised an adherent layer of macrophages and a mixture
of ﬂoating monocytic, granulocytic, and blast-like cells
(Figure S2B). These cultures were reproducibly established
in both BALB/c and C57BL6-derived cells and continued to
express exogenous AML1a as evidenced by Western blotting
with anti-RHD and anti-FLAG antibodies (Figure 4B). Flow
cytometric analysis of the nonadherent cells revealed the
following subpopulations; (1) Mac-1
 /c-kit
þ, (2) Mac-1
low/c-
kit
low, (3) Mac-1
high/c-kit
 /Gr-1
 , and (4) Mac-1
high/c-kit
 /Gr-1
þ
(Figure 4C). Expression of lymphoid (CD3, CD4, CD8, CD5,
CD25, B220, CD19, IL7-receptor alpha, AA4.1, BP-1, and
NK1.1) and erythroid (TER-119) markers was not detected; a
proportion of Mac-1
 /c-kit
þ cells expressed Sca1 (unpub-
lished data). Morphological analysis (Figure 4D) and colony-
forming assays (Figure 4E) showed Mac-1
 cells to be blast-like
with a colony-forming efﬁciency of 4%–7%, Mac-1
low cells to
be immature myeloid cells with a lower clonogenic capacity
(0.5%–0.7%), and Mac-1
high cells to be a mixture of
monocytic and granulocytic cells with no colony-forming
potential. The Mac-1
high/Gr-1
þ fraction contained exclusively
granulocytes as judged by morphology and enzymatic assays
(unpublished data). Finally, ﬂuorescence-activated cell sorter
(FACS)-puriﬁed Mac-1
 /c-kit
þ cells were able to generate all
of the other cell types observed in the cultures (unpublished
data). The use of Epo or ST-2 stromal cells to obtain in vitro
erythroid or lymphoid outputs, respectively, was not success-
ful, however (unpublished data). These results suggest that
AML1a-expressing Mac-1
 /c-kit
þ cells are capable of self-
renewal and myelomonocytic differentiation in vitro.
We next transplanted cells from these proliferating in vitro
cultures into lethally irradiated syngeneic mice together with
a radioprotective dose of fresh BM cells. We found 30%–40%
of harvested spleen and BM cells expressed GFP, demonstrat-
ing successful engraftment of cultured AML1a-transduced
cells 10 to 20 d after the transplantation (unpublished data).
Engraftment was predominantly myelomonocytic (Figure 4F),
but GFP
þ cells contributed to the erythroid (TER-119) and B-
lymphoid (B220, CD19) lineages; given the predominance of
myelomonocytic Mac
þ cells within the GFP
þ fraction, this
contribution to erythroid and B-lymphoid lineages is most
clearly apparent in the GFP
þ/Mac-1
  fraction (Figure 4G).
GFP
þ cells did not contribute, however, to the thymus, nor
were CD3
þ cells seen in BM or spleen. These ﬁndings
demonstrate that the cultured AML1a-transduced cells have
erythroid and B-lymphoid as well as myeloid differentiation
potential. The engraftment of these cultured AML1a-trans-
duced cells was not persistent, however, with virtually no
GFP
þ cells being detectable in the BM or spleen of the
transplanted animals at 5 wk post-transplant and thereafter.
Collectively, these data suggest that AML1a expression
maintains short-term reconstituting multipotent progenitors
prolonged in vitro culture.
Analysis of AML1 Isoforms in Human Cord Blood
Taken together, the data obtained in mouse cells raised the
possibility that AML1 may have some utility in the setting of
expansion of human cord blood-derived stem and progenitor
cells. We therefore next assessed the expression of AML1
isoforms in different cellular compartments of human cord
blood, which is a rich source of stem and progenitor cells. For
these experiments a quantitative competitive reverse tran-
scription-PCR strategy was used (see Methods). Total AML1
(AML1a þ AML1b/c) expression was similar in progenitor
(CD34
þ) and myelomonocytic (CD15
þ)s u b s e t s ,a n db y
comparison substantially was reduced in the erythroid
(CD36
þ) compartment (Figure 5A). In contrast, AML1a
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Isoform-Specific Effects of AML1Figure 3. Myeloid Potential of AML1a-o rAML1b-Transduced Cells
(A) Frequency of CFCs in serial replating experiments; we sorted 1310
4 GFP
þcells immediately after infection with GFP vector-only, AML1a-containing,
or AML1b-containing viruses, and they were plated. For replating, cultures were harvested on day 7 and 1310
4 cells replated. Representative data from
no fewer than three independent experiments conducted in triplicate are presented. Kruskal-Wallis test showed statistical significance of difference (p ,
0.05) of colony numbers generated by the three populations (GFP, AML1a, and AML1b) in rounds 2, 3, and 4, but not in round 1. Difference of any given
two populations was therefore analysed in rounds 2, 3, and 4, by Mann-Whitney test, with asterisks indicating statistical significance of the difference.
(B) Representative cell-cycle analyses of control and AML1a-o rAML1b-transduced cells from the second round of replating are presented. Cells
harvested from CFC assays were pulsed with BrdU and analysed for BrdU incorporation along with DNA content.
(C) Graphical summary of cell-cycle data from four independent experiments. Kruskal-Wallis test showed statistical significance of difference (p , 0.01)
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Isoform-Specific Effects of AML1expression was only observed in progenitor (CD34
þ) but not
myelomonocytic (CD15
þ) or erythroid (CD36
þ) compartments
(Figure 5B). CD34
þ cells were therefore subfractionated into
CD133
þ (primitive), CD33
þ (immature), CD19
þ (B-lymphoid),
and CD14
þ (macrophage/monocyte) progenitor subsets. Total
AML1 expression was highest in CD34
þCD133
þcells, followed
by CD34
þCD33
þ, then CD34
þCD14
þ, and ﬁnally CD34
þCD19
þ
cells (Figure 5A). The AML1a to AML1b/AML1c ratio was
about 1:6 in CD34
þCD33
þ, 1:30 in CD34
þCD133
þ, and 1:100 in
both CD34
þCD19
þ and CD34
þCD14
þ cells (Figure 5B).
Collectively, these ﬁndings suggest that AML1 is relatively
abundant in stem/early myeloid progenitors and under-
represented in erythroid progenitors. Thus, while expression
of AML1b/AML1c predominated in all fractions analysed,
AML1a expression was restricted to CD34
þ progenitor
compartments and within these were relatively most enriched
in the CD34
þCD33
þ subset. We next examined expression of
AML1 isoforms in cord blood cells at the level of protein. Cell
extracts of CD34
þ and CD34
  CB cells from two different
individuals were analysed by Western blotting. Although
technically difﬁcult given the low cells numbers available, the
results suggest that AML1a expression is restricted to the
CD34
þ compartment where it constitutes a signiﬁcant
fraction of the total AML expressed (Figure 5C). These
expression data, particularly the protein data, raise the
possibility that expression of AML1a may be relevant to the
function of primitive human haematopoietic cell compart-
ments. We explored this possibility functionally by construct-
ing a lentiviral expression vector for AML1a (Figure 6A),
using it to transduce CB cells, and subsequently assessed their
behaviour in vitro and in vivo. AML1a lentivirus-transduced
CD34
þCD38
  human CB cells were initially assessed in LTC-
IC assays on M2-10B4 and SI/SI stromal layers. AML1a-
expressing (GFP
þ) colonies appeared larger than their GFP-
control counterparts (Figure 6B), and LTC-IC frequency was
signiﬁcantly enriched (approximately 3-fold) in the GFP
þ
fraction (Figure 6C). Similar results were obtained in CAFC
assays conducted on MS-5 stromal cells (unpublished data),
and in this case cells could be retrieved from the culture and
examined immunophenotypically. The results show an
increase (approximately 9-fold) in the proportion of primi-
tive cells (CD34
þCD38
 ) within the GFP
þfraction (Figure 6D).
In light of these observations, we assessed the functional
potential of AML1a-transduced cells in a xenotransplant
setting. CD34
þCD38
  CB cells were transduced with AML1a
lentivirus and injected into irradiated NOD-SCID recipients,
and human cell engraftment assessed at eight weeks. AML1a-
expressing cells successfully engrafted, and more importantly,
the proportion of CD34
þCD38
  cells was approximately 3-
fold higher within the GFP
þ fraction of the graft (Figure 6E).
Consistent with this, functional assessment of primitive cell
activity within the GFP
þ and GFP
  fractions of the graft using
LTC-IC assays revealed a 3-fold increase in the GFP
þ (i.e.,
AML1a-expressing) population (Figure 6F). Taken together,
these results indicate that AML1a has the capacity to enhance
primitive hematopoietic cell function in human cord blood
both in vitro and in vivo.
Discussion
Here, we show that AML1a increases the competitive
engraftment potential and in vitro proliferation capacity of
primitive BM compartments, while AML1b exhibits an
essentially opposing activity, promoting differentiation and
abrogating engraftment. Expression of AML1a in human cord
blood-derived hematopoietic cells gave results broadly in line
with those obtained in mouse cells.
Although AML1/RUNX1 has been shown to be critically
involved in the generation and maintenance of hemato-
poietic stem and progenitor cells as well as the differentiation
of their progeny, the precise roles of its different isoforms in
these processes is not as yet fully understood [44,45]. Most
studies have focused on the role of Aml1 in the speciﬁcation
of HSC either in knockout mice or using the hematopoietic
differentiation of embryonic stem cells as a model [46–48].
These studies indicate that expression of Aml1b or an Aml1b
molecule that lack its carboxyl-terminal (VPRWY) repression
domain is sufﬁcient to rescue deﬁnitive hematopoiesis in
Aml1-deﬁcient cells or animals. In contrast AML1 moieties
that lack the transactivation domain, and hence may be
considered AML1a-like, are unable to rescue hematopoiesis.
Elegant as these studies are they do not directly address the
physiological role of AML1a in homeostatic adult hematopoi-
esis, its potential as a nonphysiological but therapeutic
regulator of the adult stem and progenitor compartment,
nor its pathological activity in leukaemia. Here we have
approached these issues and provided evidence that the
AML1a and AML1b isoforms have opposing effects on
hematopoietic stem and progenitor cells. Most notably, in
murine cells we have shown that expression of AML1b
abrogates hematopoietic reconstitution in an experimental
transplant setting, whereas expression of AML1a signiﬁcantly
enhances competitive engraftment potential in both primary
and secondary recipients. In mice transplanted with AML1a-
transduced cells, the frequency of primitive progenitors was
signiﬁcantly enlarged. CAFC activity was increased 14-fold
relative to controls, and the frequency of LTC-IC in the lin
 
compartment increased 4-fold; since the lin
  compartment
was itself more than 3-fold increased, the overall increase in
total LTC-IC was at least 12-fold in AML1a-transduced versus
untransduced cells. Committed progenitor activity (as judged
by CFC assays) in the AML1a-expressing component of the
grafts was also increased, but to a lesser degree, and the
colonies produced were larger, suggesting increased prolif-
of the three populations (GFP, AMl1a, and AML1b) and Mann-Whitney tests showed statistical significance of the difference between any given two
populations (p , 0.05).
(D) Colony types formed in multimyeloid conditions (upper bar graph) are shown. After typing on day 7, cultures were harvested for cytospin
preparations and differential counting (lower bar graph).
(E) CFU-meg formation was analysed. BM cells from 5-FU-treated BALB/c mice were infected with viruses for vector-alone, AML1a, and AML1b, and then
sorted into GFP
þ and GFP
  cells for colony assays (triplicate). Two experiments yielded a similar result. Asterisks indicate statistical significance of the
difference estimated by Mann-Whitney test.
(F) FACS analysis for myeloid-differentiation markers (Gr-1 and Mac-1) on cells harvested from colonies at the first and second replating.
(G) Photomicrograph of AML1a-transduced cells harvested from second replating.
doi:10.1371/journal.pmed.0040172.g003
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Isoform-Specific Effects of AML1eration, but they exhibited no block in myeloid differ-
entiation. Since AML1b abrogated engraftment, further
comparison with AML1a was necessarily conducted in vitro.
Here AML1b promoted granulocytic differentiation whereas
AML1a enhanced self-renewal as judged by colony replating
and gave rise to larger colonies, which were somewhat
retarded, although not arrested, in granulocyte differentia-
tion.
Cell-cycle analysis suggested that this growth advantage was
the result of increased proliferation as opposed to decreased
apoptosis. These in vitro effects of AML1a are broadly in
agreement with results obtained by forced expression of
AML1a in myeloid cell lines in which granulocytic differ-
entiation was blocked, and this blockade was accompanied by
uncompromised cell growth [26]. Most remarkably, AML1a-
transduced BM cells were able to expand in a simple culture
with SCF and IL3, with immature (c-kit
þlin
 ) cells proliferat-
ing vigorously yet retaining the ability to produce terminally
differentiated myelomonocytic cells in vitro and giving rise to
short-term multilineage engraftment in vivo. These extended
in vitro cultures established by AML1a-transduced cells thus
recapitulate many aspects of hematopoiesis, retaining multi-
potency in a manner reminiscent of human CD34
þ cells
programmed to express the AML1-ETO oncoprotein [49].
Both AML1a and AML1-ETO are thought to interfere with
AML1b/c, and possibly also AML2 and AML3, in a dominant-
negative fashion, either by directly competing for AML-
binding sites on DNA or by sequestering subunit b of core
Figure 4. Extended Culture and Engraftment Potential of AML1a-Transduced Cells
Cells harvested from the third replating of AML1a-transduced cells were cultured in medium containing SCF þ IL3. Cells were counted weekly and
replated at 1 3 10
5 cells per millilitre in fresh medium and cytokines. Successful long-term cultures were established in four out of four experiments
using either cells derived from BALB/c or C57BL6 mice.
(A) Fold increase of cell number are presented on a logarithmic scale versus time.
(B) Western blot analysis of cultured AML1a-transduced cells using anti-AML1 (anti-RHD) and anti-FLAG antibodies.
(C) Flow cytometric analyses of the cultured AML1a-transduced cells using anti-c-kit and anti-Mac-1 (left) and anti-Gr-1 and anti- Mac-1 (right)
antibodies.
(D) May-Grunwaldt-Giemsa staining of the sorted Mac-1
 , Mac-1
low, and Mac-1
high cells in culture.
(E) CFC activity of sorted Mac-1
 , Mac-1
low, and Mac-1
high cells in SCF and IL3. Typical data from three independent experiments conducted in triplicate
are presented. Kruskal-Wallis test showed statistical significance (p , 0.05) of the three populations (Mac-1
 , Mac-1
low, and Mac-1
high), and Mann-
Whitney tests showed statistical significance of the difference (p , 0.05) of any given two populations.
(F and G) Engraftment and lineage potential were analysed. Mice were lethally irradiated and transplanted with 10
7 cultured AML1a-transduced cells
and 5 3 10
5 fresh ‘‘radioprotective’’ BM cells to mitigate against immediate effects of lethal radiation. BM and spleen cells were gated for GFP and
analysed for lineage markers ten days after transplantation. Gr-1 (granulocytic) and Mac-1 (myeloid) expression in BM and spleen were analysed (F).
Given the predominance of Mac-1
þcells in the graft, Mac-1
 cells were analysed for TER-119 (erythroid), B220 (B-lymphoid), and CD19 (B-lymphoid) (G).
Grey shading shows marker expression, and the black dotted lines show profiles of isotype-matched control antibodies. Representative data from three
independent experiments are shown.
doi:10.1371/journal.pmed.0040172.g004
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Isoform-Specific Effects of AML1binding factor (CBFb), an obligate subunit required for
binding of AML proteins to DNA [3]. Thus comparison of the
results obtained with our AML1a mice to those reported for
AML1-ETO and Aml1-targetted animals should be informative
with respect to understanding physiological and pathological
AML1 activities. Like AML1a animals, ‘‘haploinsufﬁcient’’
Aml1
þ/  mice also exhibit increased CFU-GM and CFU-mix,
but unlike AML1a mice, the size of colonies generated is
unaffected [50]. BM cells of the Aml1
þ/ mice exhibit increased
competitiveness accompanied by a nearly doubled frequency
of immature hematopoietic stem and progenitors as assessed
in CAFC assays [50]. The KSL fraction is increased in the BM
Figure 5. Expression of AML1 Isoforms in Human Hematopoietic Compartments
Human blood cells from three pooled individual umbilical cord samples were sorted on the basis of the cell surface molecules indicated, and the levels
of transcripts corresponding to different AML1 isoforms were quantitated in triplicate and normalized relative to G6PD.
(A) Total AML1 transcript levels are presented as relative levels of that observed in CD36
þ cells.
(B) The fraction of AML1a relative to total AML1 transcripts was determined. In (A) and (B) Kruskal-Wallis test showed statistical significance of difference
among the fractions (p , 0.01). Mann-Whitney tests were then used to estimate the difference of any given two fractions, with asterisks indicating the
statistical significance (p , 0.05). N.S., not significant.
(C) Western blot analysis of AML-isoform expression using the anti-RHD antibody in CD34
þ and CD34
  fractions of human cord blood (4 3 10
5 cells
each) from two individual healthy donors. Analysis of actin expression in the same samples provide a control for loading.
doi:10.1371/journal.pmed.0040172.g005
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Isoform-Specific Effects of AML1Figure 6. Forced Expression of AML1a in Human Cord Blood Cells
(A) Lentiviral construct used for transduction.
(B) Photomicrograph of typical LTC-IC colonies derived from AML1a-expressing (GFP
þ) and control (GFP
 ) human cord blood cells.
(C) Frequency of LTC-IC in AML1a-expressing (GFP
þ) and control (GFP
 ) human cord blood cells.
(D) Representative FACS analysis of AML1a-transduced (GFP
þ) and control (GFP
 ) cells recovered after 5 wk of culture on MS-5 stromal layers. Right plot
shows graphical summary of all experiments performed.
(E) Representative FACS analysis of AML1a-expressing (GFP
þ) and control (GFP
 ) human cells engrafted in the BM of NOD-SCID mice at 8 wk (left plot).
Right plot shows graphical summary of all experiments performed.
(F) Frequency of LTC-IC in human cells derived from primary NOD-SCID mice engrafted with AML1a-transduced cells.
In (C), (D), (E), and (F), Mann-Whitney test showed statistical significance of the difference (p , 0.05).
doi:10.1371/journal.pmed.0040172.g006
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 /  mice, and hematopoietic recon-
stitution ability in transplanted mice maintained; yet Aml1
 / 
hematopoietic cells are defective in competitive repopulation
capacity [8]. Mice reconstituted with AML1a-transduced cells
did not show appreciably inhibited myeloid differentiation,
in contrast to mice reconstituted with hematopoietic cells
retrovirally transduced with AML1-ETO [51,52]. These ﬁnd-
ings imply that while some aspects associated with forced
AML1a expression mimic reduced dosage, although not
complete loss, of Aml1, AML1a confers unique effects on
stem and progenitor cell properties that cannot be achieved
by reducing the dosage of the Aml1 gene or by expression of
the AML1-ETO oncoprotein. Of note here also are our
preliminary results obtained with a mutant of AML1
(AML1R139G), which can sequester CBFb but cannot bind
DNA [53]. Like AML1a, AML1R139G-transduced cells ex-
hibited delayed granulocytic differentiation in vitro. Unlike
AML1a, AML1R139G-transduced cells did not produce long-
term cultures in vitro and did not contribute to long-term
hematopoiesis in vivo (ST, unpublished data). Thus, the
ability of AML1a to bind DNA appears crucial for cell
expansion, thereby further emphasising that AML1a is not a
simple antagonist of AML1b/c or AML2/AML3, but rather
exerts distinct effects on hematopoietic cells by virtue of its
DNA-binding activity. Although we have in this study
concentrated on the role of AML1a, the observation that
AML1b can abrogate engraftment, presumably through
enhancing granulocytic differentiation, is of interest and
perhaps at ﬁrst glance surprising. However it is now well
documented that transcription factor effects are highly dose
sensitive. Aml1 is itself a case in point [54], and GATA-2
[55,56], PU1 [57], and OCT4 [58] provide additional examples.
Recent modelling approaches [59] (S. Huang and TE,
unpublished data) are starting to illuminate how dose-
sensitive bi-stable switches can be created as a result of the
transcriptional motifs (coherent and incoherent feedforward
motifs, crossantagonistic motifs, and the like) adopted by
transcription factors. While such dynamic models and the
genetic regulatory networks on which they are based [60] do
not as yet include Aml1, the fact that Aml1is a key regulator of
granulocyte/monocyte-afﬁliated growth factor receptors as
well as transcription factors provides a plausible framework
for understanding how increasing its expression could lead to
enhanced differentiation at the expense of self-renewal.
In light of the AML1a activities highlighted by our
experiments, it is intriguing that AML1a transcripts are
evident in selected samples of leukaemia [23]. AML1 mutants
devoid of the carboxyl-terminal portion of the molecule, and
thereby structurally resembling AML1a, are also found in BM
cells of some patients with myelodysplastic syndrome and
myeloid leukaemia [27–29]. Collectively, AML1a or disease-
associated AML1a-like AML1 molecules could be implicated
in increased proliferation or competitiveness at key stages of
hematopoietic differentiation. Further analysis of the mech-
anisms involved will be of therapeutic interest in the context
of hematopathology and may inform attempts to expand
transplantable hematopoietic stem/progenitor cells for cell
therapy. Of particular interest as a stem cell source is cord
blood. It is widely available through cord-blood banks, is
applicable across human leukocyte antigen mismatches, and
carries low risks of infectious disease transmission [61].
Despite these merits, slow engraftment and limited cell
numbers contained in a given umbilical cord increases the
likelihood of serious infectious complications and limits
widespread application to adult patients. Modest expansion
of stem and progenitor cells would be expected to circumvent
these drawbacks [62], and thus AML1a-mediated mechanisms
may therefore prove useful in the facilitation of trans-
plantation therapeutics. Our experiments on human cord
blood cells support this view. We have shown at the RNA level
that AML1a is predominantly expressed within the primitive
CD34
þCD133
þ and CD34
þCD33
þ compartments of human
cord blood. Although human HSCs have not been fully
characterized, these compartments are thought to contain
the bulk of HSCs and multipotent progenitors [63–66]. Thus
it is plausible that expansion of hematopoietic cells could be
normally affected, in part, by AML1a expression by a
combination of antagonism of AML1b but also through
AML1a-speciﬁc pathways (see above). It should be stressed,
however, that in all these compartments, at least at steady
state, AML1b transcripts are signiﬁcantly more abundant than
those of AML1a. However, analysis of relative protein
abundance in CD34
þ versus CD34
  cells suggests that AML1a
may comprise a signiﬁcant fraction of total AML1 protein in
the CD34
þ compartment. Whatever the physiological role of
AML1a, our forced expression experiments indicate that it
has the capacity to enhance primitive hematopoietic cell
activity in cord blood; forced expression of AML1a in
primitive CD34
þCD38
  cord blood-derived cells resulted in
increased LTC-IC activity, increased proportions of immu-
nophenoptypically primitive cells in long-term MS-5 stromal
cultures, and most importantly, enhanced primitive cell
activity in vivo assessed in the NOD-SCID mouse model.
Identiﬁcation and exploitation of processes that normally
regulate the relative balance of AML1a and AML1b could
therefore provide one strategy to potentiate the engraftment
activity of human hematopoietic stem and progenitor cells.
Alternatively direct introduction of AML1a protein as a
trans-activating transduction-fusion, along the lines pro-
posed for TAT-HOXB4 [19], could be considered. In any
event, our results identify AML1a as one of the few molecules
[19] with the capacity for increasing the engraftment
potential of hematopoietic stem and progenitor cells. In
summary, our ﬁndings are of interest with respect to both the
physiological and pathological roles of AML1 isoforms and
have clear implications for hematopoietic cell transplanta-
tion.
Supporting Information
Figure S1. BM Cells from 5-FU-Treated Mice Were Transduced with
AML1a-Containing or Control Retrovirus and Transplanted into
Lethally Irradiated Syngeneic Hosts
The following analyses were conducted 4 mo after the trans-
plantation.
(A) FACS analysis of the primitive c-kit
þlin
  (B220, CD3, CD4, CD8,
CD5, Gr-1, Mac-1, and TER-119) progenitor compartment. Results
are shown from the GFP
þ and GFP
  fractions of a typical AML1a
animal. GFP
þ cells from a typical mouse receiving vector-only-
transduced cells provide a control.
(B) Proportion of cells representative of different myeloid matura-
tion stages and erythroid and lymphoid lineages in GFP
þ BM cells
from a typical vector-only or AML1a animal.
(C) Cytospins of GFP
þ BM cells from a typical vector-only animal (a),
GFP
  (b), and GFP
þ (c) cells from a typical AML1a animal.
Found at doi:10.1371/journal.pmed.0040172.sg001 (5.5 MB PPT).
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Isoform-Specific Effects of AML1Figure S2. BM Cells from 5-FU-Treated Mice Were Transduced with
AML1a-Containing, AML1b-Containing, or Control Retrovirus and
Cultured under Multimyeloid Differentiation Conditions
(A) Photomicrograph of typical colonies derived from control,
AML1a-, or AML1b-transduced BM cells at the second round of re-
plating.
(B) Photomicrographs of cells from 8-wk-old suspension cultures
derived from AML1a-expressing colonies obtained at the third round
of replating (see text for details). May-Grunwaldt-Giemsa staining of
the adherent (upper image) and ﬂoating cells (lower image).
Found at doi:10.1371/journal.pmed.0040172.sg002 (1.0 MB PPT).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession numbers of the
genes discussed in this paper are AML1a (D43967), AML1b (D43968),
AML1c (D43969), Aml1 (NM_009821), GATA-1 (X17254), SCL/TAL
(NM_003189), TEL/ETV6 (NM_001987), and IKAROS/IKZF (U40462).
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Isoform-Specific Effects of AML1Editors’ Summary
Background. Blood contains red blood cells (which carry oxygen round
the body), platelets (which help the blood to clot), and white blood cells
(which fight off infections). All these cells, which are regularly replaced,
are derived from hematopoietic stem cells, blood-forming cells present
in the bone marrow. Like all stem cells, hematopoietic stem cells self-
renew (reproduce themselves) and produce committed progenitor cells,
which develop into mature blood cells in a process called hematopoiesis.
Many proteins control hematopoiesis, some of which are called
transcription factors; these factors bind to DNA through their DNA-
binding domain and then control the expression of genes (that is, how
DNA is turned into proteins) through particular parts of the protein (their
transcription regulatory domains). An important hematopoietic tran-
scription factor is AML1—a protein first identified because of its
involvement in acute myelogenous leukemia (AML, a form of blood
cancer). Mutations (changes) in the AML1 gene are now known to be
present in other types of leukemia, which are often characterized by
overproliferation of immature blood cells.
Why Was This Study Done? Because of AML19s crucial role in
hematopoiesis, knowing more about which genes it regulates and
how its activity is regulated could provide clues to treating leukemia and
to improving hematopoietic cell transplantation. Many cancer treat-
ments destroy hematopoietic stem cells, leaving patients vulnerable to
infection. Transplants of bone marrow or cord blood (the cord that links
mother and baby during pregnancy contains peripheral blood stem cells)
can replace the missing cells, but cord blood in particular often contains
insufficient stem cells for successful transplantation. It would be useful,
therefore, to expand the stem cell content of these tissues before
transplantation. In this study, the researchers investigated the effect of
AML1 on self-renewal and differentiation of hematopoietic stem and
progenitor cells in the laboratory (in vitro) and in animals (in vivo). In
particular, they have asked how two isoforms (closely related versions) of
AML1 affect the ability of these cells to grow and differentiate (engraft) in
mice after transplantation.
What Did the Researchers Do and Find? The researchers artificially
expressed AML1a and AML1b (both isoforms contain a DNA binding
domain, but only AML1b has transcription regulatory domains) in mouse
hematopoietic stem and progenitor cells and then tested the cells’ ability
to engraft in mice. AML1a-expressing cells engrafted better than
unaltered cells and outgrew unaltered cells when transplanted as a
mixture. AML1b-expressing cells, however, did not engraft. In vitro,
AML1a-expressing cells grew more than AML1b-expressing cells, where-
as differentiation was promoted in AML1b-expressing cells. To inves-
tigate whether the isoforms have the same effects in human cells, the
researchers measured the amount of AML1a and AML1b mRNA (the
template for protein production) made by progenitor cells in human
cord blood. Although AML1b (together with AML1c, an isoform with
similar characteristics) mRNA predominated in all the progenitor cell
types, the relative abundance of AML1a was greatest in the stem and
progenitor cells. Furthermore, forced expression of AML1a in these cells
improved their ability to divide in vitro and to engraft in mice.
What Do These Findings Mean? These findings indicate that AML1a
expression increases the self-renewal capacity of hematopoietic stem
and progenitor cells and consequently improves their ability to engraft in
mice, whereas AML1b expression encourages the differentiation of these
cell types. These activities are consistent with the expression patterns of
the two isoforms in normal hematopoietic cells and in leukemic cells—
the mutated AML made by many leukemic cells resembles AML1a.
Because the AML1 isoforms were expressed at higher than normal levels
in these experiments, the physiological relevance of these findings needs
to be confirmed by showing that normal levels of AML1a and AML1b
produce similar results. Nevertheless, these results suggest that
manipulating the balance of AML1 isoforms made by hematopoietic
cells might be useful clinically. In leukemia, a shift toward AML1b
expression might slow the proliferation of leukemic cells and encourage
their differentiation. Conversely, in cord blood transplantation, a shift
toward AML1a expression might improve patient outcomes by expand-
ing the stem and progenitor cell populations.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040172.
  Wikipedia has pages on hematopoiesis and hematopoietic stem cells
(note: Wikipedia is a free online encyclopedia that anyone can edit;
available in several languages)
  The US National Cancer Institute has a fact sheet on bone marrow and
peripheral blood stem cell transplantation (in English and Spanish) and
information for patients and professionals on leukemia (in English)
  The American Society of Hematology provides patient information
about blood diseases, including information on bone marrow and
stem cell transplantation
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